India Plans to Cap Drug Distributors’ Profit Margins at 30%

The Indian government is planning to cap the business profit margin of medicine distributors at a maximum of 30% based on their costs, in a move aimed at reducing the prices of expensive medicines.

The proposed measure will cover high-cost cancer medicines as well as certain patented drugs. If implemented at the proposed rate, the maximum retail prices of some medicines could fall by as much as 70%.

A significant reduction in cancer drug prices could provide major relief to patients, particularly those facing high treatment costs. The government is considering the move as part of efforts to curb excessive profits in the cancer medicine market.

In 2019, India introduced a profit margin cap on 42 cancer medicines on a trial basis. The latest initiative is being considered as a continuation of that policy.

The new rules are expected to take effect within the next 10 days. However, their actual impact will depend on several factors, including which medicines are ultimately included.

Authorities are preparing a list of medicines that could come under the new rules. The selection process will consider whether the drugs are approved and widely used for cancer treatment in India.

According to sources in the Department of Pharmaceuticals, the price of a medicine will be an important factor in determining whether it is covered by the proposed cap.

For lower-priced medicines, imposing a 30% margin limit could discourage pharmaceutical companies from marketing them, as the permitted margin may not be sufficient to cover marketing and distribution costs, the sources said.

The government therefore wants to focus the new rules on medicines whose high prices have a significant impact on patients’ overall treatment costs.

Officials said the government does not plan to impose a blanket price cap on all medicines, in order to avoid disruptions in the supply and distribution of lower-cost drugs.